Categories
Press Research

Landmark Publication Points to IC14 Target in ALS-MND

ALS-MND is our leading clinical program in neurodegeneration; however Parkinson’s and Alzheimer’s disease are also coming into sharp focus with some extraordinary new data directly related to IC14. This new publication of a landmark paper in the prestigious Nature family of journals by our close collaborators at Houston Methodist Neurological Institute, led by our colleague and friend, […]

Categories
News

FDA approves COVID-19 study

On June 3, the US FDA approved an Investigative New Drug (IND) application for IC14 together with remdesivir in 300 COVID-19 patients at risk of acute respiratory distress syndrome (ARDS). Details of this study may be found at clinicaltrials.gov. The Company expects to be able to announce details of the sponsorship of this breakthrough phase […]

Categories
Press Research sCD14

New research links IC14 target to dementia

New research published in the world’s leading journal Neurology reports a link between higher levels of an inflammatory marker called sCD14 and a higher risk of developing dementia.  The study looked at blood samples and dementia diagnosis of more than 4,700 people over a decade. Researchers found that people with higher blood levels of sCD14 […]

Categories
News

Australian Immunotherapy Selected for Revolutionary US Clinical Trial Platform Debut

An Australian immunotherapy drug will receive a huge boost when it is tested with four other new concepts across 54 clinical sites across the USA in a search for an effective treatment for ALS (a motor neuron disease). This bold initiative will see Implicit Bioscience’s IC14 entering an elite pivotal clinical study in the first […]